Later on, investigators at Baylor College of Medicine conducted various trials to determine the safety and antitumor efficacy of HER2-CAR CMV-CTLs and showed a successful generation and evaluation in 16 HER2+ glioblastoma patients (NCT01109095). This evidence concerns the gene ERBB2 and glioblastoma.